{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:53:31Z","timestamp":1781196811546,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.14219\/jada.archive.2008.0016","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:43:42Z","timestamp":1389228222000},"page":"23-30","source":"Crossref","is-referenced-by-count":140,"title":["Bisphosphonate Use and the Risk of Adverse Jaw Outcomes"],"prefix":"10.1016","volume":"139","author":[{"given":"Vassiliki M.","family":"Cartsos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios I.","family":"Zavras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.14219\/jada.archive.2008.0016_bib1","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"issue":"22","key":"10.14219\/jada.archive.2008.0016_bib2","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.14219\/jada.archive.2008.0016_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.14219\/jada.archive.2008.0016_bib4","author":"U.S. Food and Drug Administration"},{"key":"10.14219\/jada.archive.2008.0016_bib5","author":"U.S. Food and Drug Administration"},{"issue":"3","key":"10.14219\/jada.archive.2008.0016_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.otohns.2006.11.008","article-title":"Bisphosphonates and jaw osteonecrosis: the UAMS experience","volume":"136","author":"Clarke","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.14219\/jada.archive.2008.0016_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","article-title":"Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?","volume":"64","author":"Zavras","year":"2006","journal-title":"J Oral Maxillofac Surg"},{"issue":"9","key":"10.14219\/jada.archive.2008.0016_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"10.14219\/jada.archive.2008.0016_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"10.14219\/jada.archive.2008.0016_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjmed.2004.04.015","article-title":"Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity","volume":"117","author":"Lugassy","year":"2004","journal-title":"Am J Med"},{"issue":"2","key":"10.14219\/jada.archive.2008.0016_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.14219\/jada.archive.2008.0016_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.14219\/jada.archive.2008.0016_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.14219\/jada.archive.2008.0016_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.joms.2004.03.005","article-title":"Osteonecrosis and bisphosphonates: correlation versus causation","volume":"62","author":"Schwartz","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"10.14219\/jada.archive.2008.0016_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"10.14219\/jada.archive.2008.0016_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.14219\/jada.archive.2008.0016_bib17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jnci\/djm025","article-title":"Intravenous bisphosphonates therapy and inflammatory conditions or surgery of the jaw: a population-based analysis","volume":"99","author":"Wilkinson","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.14219\/jada.archive.2008.0016_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"22","key":"10.14219\/jada.archive.2008.0016_bib19","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw: do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14219\/jada.archive.2008.0016_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/pds.781","article-title":"Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future","volume":"12","author":"Layton","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.14219\/jada.archive.2008.0016_bib21","unstructured":"Zavras AI, Brown T, Chan A. Albert D. Medical\/dental insurance databases and drug safety surveillance. Workshop presented at: American Association for Dental Research Meeting and Exhibition; March 10, 2006; Orlando, Fla."},{"issue":"5","key":"10.14219\/jada.archive.2008.0016_bib22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/02841860601185917","article-title":"Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis","volume":"46","author":"Ortega","year":"2007","journal-title":"Acta Oncol"},{"key":"10.14219\/jada.archive.2008.0016_bib23","unstructured":"Zavras AI, Wilkinson GS. Signal detection in the evaluation of bisphoshonate-associated osteonecrosis of the jaw. Poster presented at: 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; Aug. 22, 2005; Lisbon, Portugal."},{"issue":"7","key":"10.14219\/jada.archive.2008.0016_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"10.14219\/jada.archive.2008.0016_bib25","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714614069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714614069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T13:20:16Z","timestamp":1538918416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817714614069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0002817714614069"],"URL":"https:\/\/doi.org\/10.14219\/jada.archive.2008.0016","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}